✨ Free AI Report
PaxMedica, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Research Preview PaxMedica, Inc.
Research Preview

PaxMedica, Inc.: Business Overview, Financials & Competitive Analysis

PaxMedica is a clinical stage biopharmaceutical company focused on developing anti-purinergic drug therapies for neurologic disorders. Its lead product PAX-101, an IV formulation of suramin, is in Phase 3 trials for a...

Analyst-debate audio for PaxMedica, Inc.

AskCyborg analysts argue the bull and bear cases for PaxMedica, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
PaxMedica, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below
3/ 10Challenged

Cyborg Score thesis

High-risk clinical-stage biotech with potentially significant upside if Phase 3 trials succeed, but currently facing severe...

Read the full analyst-debate transcript →
Industry Biopharmaceutical / Clinical-Stage Drug Development
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: June 15, 2026
AI-Verified Research
30+ Page Report

Get the Latest PaxMedica, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

PaxMedica, Inc. Overview

Pro stress-test →

PaxMedica is a clinical stage biopharmaceutical company focused on developing anti-purinergic drug therapies for neurologic disorders. Its lead product PAX-101, an IV formulation of suramin, is in Phase 3 trials for autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and other neurological conditions.

Strategic Profile

Pro stress-test →

The company was formerly known as Purinix Pharmaceuticals and rebranded to PaxMedica in April 2020. PaxMedica listed on NASDAQ in August 2022, pursuing specialized immunological and neurological drug development with a focus on rare and unmet medical needs in neurodevelopmental disorders.

Competitive Landscape

Pro stress-test →

PaxMedica competes in the rare neurological disease biotech space against larger players like Biohaven, Sage Therapeutics, and other autism/neurological disorder specialists. The company's unique anti-purinergic approach and multi-indication pipeline provide differentiation, though financial constraints limit competitive positioning.

Industry Context

PaxMedica, Inc. operates in Biopharmaceutical / Clinical-Stage Drug Development.

Key facts

Founded: 2018 · Headquarters: Tarrytown, New York, US · Market cap: $12.6K

What the analysts stress-tested

The top findings that survived the multi-agent debate for PaxMedica, Inc..

+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

Get alerted when PaxMedica, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Sage TherapeuticsCNS-focused biopharmaceutical company→Biohaven PharmaceuticalsRare neurological disorder treatment focus→Akcea TherapeuticsNeurological and neuroinflammatory disease focus→

Compare PaxMedica, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

PaxMedica, Inc. operates in Biopharmaceutical / Clinical-Stage Drug Development. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceutical / Clinical-Stage Drug Development research →
NEW · MCP server

Ask your AI assistant about PaxMedica, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare PaxMedica, Inc. and its top competitor on Cyborg Score”
“What did PaxMedica, Inc. do this quarter?”
“Is PaxMedica, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does PaxMedica, Inc. do?+
PaxMedica is a clinical stage biopharmaceutical company focused on developing anti-purinergic drug therapies for neurologic disorders. Its lead product PAX-101, an IV formulation of suramin, is in Phase 3 trials for a...
What is PaxMedica, Inc.'s Cyborg Score?+
PaxMedica, Inc. has a Cyborg Score of 3/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are PaxMedica, Inc.'s main competitors?+
Named competitors include Sage Therapeutics, Biohaven Pharmaceuticals, Akcea Therapeutics. The full competitive landscape is in the AskCyborg report.
How can I get the full PaxMedica, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the PaxMedica, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track PaxMedica, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

Other strong performers across the analyst-debate framework. Click any to see their research report.

9National Bank of Pakistan9RENK Group AG9Lumentum Holdings Inc.9First Abu Dhabi Bank9The Travelers Companies, Inc.9BAE Systems plc9Arista Networks9KLA Corporation9Hermès International S.A.8Enerjisa Enerji A.Ş.8Emirates Central Cooling Systems Corporation8WALLIX Group8StealthGas Inc.8SofWave Medical Ltd.8Himalaya Shipping Ltd.8Bannerman Energy Ltd8Sembcorp Salalah Power & Water Company8MilDef Group